The female BALB/c mice (age 6–8 weeks, No. SCXKjing2012-0001, SPF/VAF, purchased from Peking University Health Science Center) were randomly divided into five groups. One day before the immunization schedule, mice were given intravenous injection of cyclophosphamide (Sigma) at a dose of 100 mg/kg per mouse as the low-dose cyclophosphamide could reduce T-regulatory cells and enhance the immune response [49 (link)]. Mice were subcutaneously (s.c.) injected with a mixture of the adjuvant (First with Freund's complete adjuvant, and then Freund's incomplete adjuvant, Sigma) and the glycoconjugate vaccine modified-STn-KLH or STn-KLH in PBS (containing 2 μg of carbohydrate) on day 1. In the negative control group, mice were immunized with a mixture of adjuvants and KLH. Each animal received a total of five immunizations at biweekly intervals. At one week after the fourth immunization, all mice were challenged with 100 μL of 2 × 106 cells/mL CT-26 tumor cell suspended in PBS by i.v. injection into the tail. The mice were bled by tail vein prior to the initial immunization and on day 13 after the third immunization. The blood was clotted to obtain sera, stored at –80°C. On day 70, the mice were bled and euthanized for a series of analysis described below. Animals used in this paper were well cared for and approved by Peking University Health Science Center.
Cyclophosphamide
Manufactured by Merck Group
Sourced in United States, Germany, France, United Kingdom, Sao Tome and Principe, Japan, Israel, China, Belgium, India, Switzerland
Cyclophosphamide is a chemical compound used as an active pharmaceutical ingredient in the production of certain medications. It is a cytotoxic agent that can interfere with cell division and proliferation. The core function of cyclophosphamide is to serve as a key component in the formulation of pharmaceutical products.
Automatically generated - may contain errors
Lab products found in correlation
Doxorubicin, by Merck Group (12 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (10 mentions)
Rpmi 1640 medium, by Thermo Fisher Scientific (8 mentions)
5 fluorouracil, by Merck Group (7 mentions)
Mitomycin c, by Merck Group (7 mentions)
Gemcitabine, by Merck Group (7 mentions)
Paclitaxel, by Merck Group (7 mentions)
Sodium azide, by Merck Group (6 mentions)
Busulfan, by Merck Group (6 mentions)
Cisplatin, by Merck Group (6 mentions)
Fetal bovine serum (fbs), by Thermo Fisher Scientific (6 mentions)
Methanol, by Merck Group (5 mentions)
Docetaxel, by Merck Group (5 mentions)
Fluconazole, by Merck Group (5 mentions)
2 nitrofluorene, by Merck Group (5 mentions)
Methotrexate, by Merck Group (5 mentions)
Etoposide, by Merck Group (5 mentions)
Acetonitrile, by Merck Group (5 mentions)
Triton x 100, by Merck Group (4 mentions)
Tween 80, by Merck Group (4 mentions)
240 protocols using cyclophosphamide
1
Vaccine-Induced Anti-Tumor Immunity in BALB/c Mice
2
Cyclophosphamide-Induced Interstitial Cystitis Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
IC model was made by injection of cyclophosphamide in the same method as described below.23 (link) To induce IC rats, the rats received intraperitoneal injection with 75 mg/kg cyclophosphamide (Sigma Chemical Co., St. Louis, MO, USA) every 3 days for 10 days (total of 3 injections). The rats in the control group received an intraperitoneal injection with the same volume of physiological saline on the same schedule. The rats in the PDRN treated groups were intraperitoneally injected with 0.5 mL physiological saline containing 8 mg/kg PDRN (Rejuvenex®, PharmaResearch Products, Pangyo, Korea), once daily for 10 days after IC induction (Figure 1 ). We selected PDRN concentration that was found to be most effective through previous studies20 (link),21 (link) and preliminary experimental result. In order to confirm that the action of PDRN occurs through the adenosine A2A receptor, 8 mg/kg DMPX (Sigma Aldrich Co.) was co-treated with PDRN.![]()
Experimental schedule.
3
FGF7p and AKT Inhibitor Modulate Cyclophosphamide-Induced Bladder Injury
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We gave mice two 20 mg/kg subcutaneous (SQ) injections of FGF7p (Narla et al., 2022 (link)) dissolved in 2.5% dimethyl sulfoxide (DMSO) (Sigma‐Aldrich, Cat# D2438) or 2.5% DMSO alone (Vehicle 1), one dose at 72 h and the other dose at 48 h before cyclophosphamide. To inhibit AKT signaling, we administered 40 mg/kg intraperitoneal (IP) injections of LY294002 (Selleckchem, Cat# S1105), a known AKT inhibitor (AKTi) dissolved in 2% DMSO (Sigma‐Aldrich, Cat# D2438) or 2% DMSO alone (Vehicle 2) concurrently with the initial dose of FGF7p and then every 12 h until termination of the experiments. To induce bladder injury with FGF7p and/or the AKTi, we administered 150 mg/kg IP injections of cyclophosphamide (Sigma‐Aldrich, Cat# C7397) dissolved in PBS. For experiments with FGF7p alone, we harvested bladders 28 days after cyclophosphamide. For experiments with FGF7p and the AKT inhibitor, we harvested bladders 24 h after cyclophosphamide.
4
Persistently Neutropenic Mouse Model of Aspergillosis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For the persistently neutropenic mouse model, we used outbred ICR (Orient Bio Inc., Seongnam-si, Korea) female mice (30 g in body weight, 6 to 8 weeks old), which were housed five per cage and had access to food and water ad libitum. Mice were immunosuppressed with intraperitoneal injections (i.p.) of cyclophosphamide (Sigma–Aldrich, USA) at 250 mg/kg for 4 days prior to infection and with cyclophosphamide at 250 mg/kg and cortisone acetate (Sigma–Aldrich, USA) injected subcutaneously at 250 mg/kg 1 day prior to infection. At day 1 and 3 day post-infection, administrations were repeated with cyclophosphamide (125 mg/kg i.p.). Mice were anesthetized with isoflurane and then intranasally infected with 1 × 107 conidia of A. fumigatus strains (10 mice per each strain) in 30 µL of 0.01% Tween 80 in PBS. Mice were observed every 12 h for survival for 4 days after challenge. Mock mice were inoculated with sterile 0.01% Tween 80 in PBS.
5
Cyclophosphamide-Induced Premature Ovarian Failure
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
POF was induced in mice according to a previously described method (3 (link)–5 (link)). Briefly, 8-week-old female C57BL/6 mice (n=40) were purchased from the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine (Shanghai, China). Mice were housed in a temperature-controlled environment under standard light-dark cycles with ad libitum access to food and water as previously described (3 (link)). Mice were randomly divided into two groups (20 mice/group). Mice in the POF group were injected intraperitoneally with 70 mg/kg cyclophosphamide (Sigma-Aldrich, St. Louis, MO, USA), followed by intraperitoneal injections of 30 mg/kg cyclophosphamide every three days for three weeks, to establish the POF mouse model. Mice in the control group were injected intraperitoneally with an equal volume of normal saline every three days for three weeks. All mice were sacrificed by cervical dislocation at three weeks and the ovaries were harvested for subsequent analysis. The study was approved by the Ethics Committee of Shanghai Geriatric Institute of Chinese Medicine (Shanghai, China; ref. SHAGESYDW2015026). All experiments conformed to standards set by the Laboratory Animal Regulation of the State Scientific and Technological Commission (www.slarc.org.cn ).
6
Murine Model of Invasive Aspergillosis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In the cyclophosphamide and corticosteroid treated (CCT) model, mice were intraperitoneally injected with 150 mg kg-1 cyclophosphamide (Sigma–Aldrich, Munich, Germany) and subcutaneously (s.c.) with 112 mg kg-1 hydrocortisone acetate (Sigma–Aldrich) on days -3 and -1 before A. fumigatus infection. In the corticosteroid treated (CT) model, mice were s.c. injected with 112 mg kg-1 hydrocortisone acetate on days -3 and -1 before infection.
7
Ovarian Destruction via Chemotherapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To destroy the ovaries, a model of chemotherapy was
created. Cyclophosphamide (Sigma, China) diluted in
normal saline was intraperitoneally (IP) injected at 50 mg/
kg at the first day, followed by 13 days injection of 8 mg/
kg daily Cyclophosphamide (19 (link)).
created. Cyclophosphamide (Sigma, China) diluted in
normal saline was intraperitoneally (IP) injected at 50 mg/
kg at the first day, followed by 13 days injection of 8 mg/
kg daily Cyclophosphamide (19 (link)).
8
Cyclophosphamide-Induced Diabetes in NOD Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cyclophosphamide has been shown to rapidly promote a high incidence of diabetes in NOD mice.15 (link),16 (link) At 11 weeks of age, 70 mice had blood drawn for baseline A1c, and then received 200 mg/kg of Cyclophosphamide (Sigma-Aldrich, St Louis, MO, USA) by intraperitoneal injection. All mice were screened for blood glucose levels three times weekly; by 13 weeks of age, 25 mice with two consecutive blood glucose levels >300 mg/dL were diagnosed as diabetic and entered into the study, and the remaining mice received a second 200 mg/kg intraperitoneal dose of Cyclophosphamide. By 15 weeks of age, an additional 14 mice (39 total) had two consecutive blood glucose levels >300 mg/dL, were diagnosed as diabetic, and were entered into the study.
9
Exosome Treatment for Premature Ovarian Failure
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Based on our previous study [5 (link), 6 (link), 36 (link)], 36 10-week-old female C57BL/6 mice were randomly divided into three groups (WT group, POF+ saline group, POF+ exosome group) with 12 rats in each group. POF mice were first intraperitoneally injected with cyclophosphamide (Sigma-Aldrich, St. Louis, MO, USA) at 70 mg/kg for 1 week, and then, cyclophosphamide was injected intraperitoneally at a dose of 30 mg/kg for 2 weeks every 2 days to establish the POF mouse model. In addition, the mice in the control group were intraperitoneally injected with the same amount of normal saline every 2 days for 3 weeks. According to a previous study [37 (link)], approximately 1 × 106 exosomes produced by AFSCs were injected into POF mice via the tail vein every 2 days for 4 weeks, and the same amount of normal saline was injected into the tail vein of the POF group. All animal experiments are conducted according to the guidelines of the National Institutes of Health on the care and use of laboratory animals. The research program was also approved by the Ethics Committee of the Experimental Animal Center of the General Hospital affiliated with Shanghai Jiao Tong University (2020AW126).
10
Isolation and Analysis of Beta-Glucan
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Ham’s F-10 was purchased from Biosera (Nuaille, France), mitomycin C and cytochalasin B were purchased from Cayman chemical company (Ann Arbor, MI, United States), Mushroom and Yeast Beta-Glucan assay kit (K-YBGL) was purchased from Megazyme (Bray, Ireland), Luna Universal PCR mix was purchased from New England Biolabs Inc. (Ipswich, MA, United States), Giemsa’s azur eosin methylene blue solution was purchased from Panreac Applichem (Castella del Valles, Spain), cyclophosphamide, DPX mounting medium, methanol, glacial acetic acid and formalin solution (neutral buffered, 10%) were purchased from Merck (Darmstadt, Germany), Fetal Bovine Serum (FBS), L -glutamine, M-MLV reverse transcriptase, Phytohemagglutinin M (PHA-M), and Trizol reagent were purchased from Thermo Fisher Scientific (Paisley, United Kingdom).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!